Copyright © 2012 American Medical Association. All rights reserved. From: Tests and Expenditures in the Initial Evaluation of Peripheral Neuropathy Arch Intern Med. 2012;172(2):127-132. doi:10.1001/archinternmed.2011.1032 Figure Legend: Figure 1. Utilization of diabetic and American Academy of Neurology–recommended tests in 1031 patients with peripheral neuropathy. GTT indicates glucose tolerance test; HbA1c, hemoglobin A1c; and SPEP, serum protein electrophoresis. Date of download: 10/24/2017 Copyright © 2012 American Medical Association. All rights reserved.
Copyright © 2012 American Medical Association. All rights reserved. From: Tests and Expenditures in the Initial Evaluation of Peripheral Neuropathy Arch Intern Med. 2012;172(2):127-132. doi:10.1001/archinternmed.2011.1032 Figure Legend: Figure 2. Utilization of electromyography (EMG) and magnetic resonance imaging (MRI) in 1031 patients with peripheral neuropathy. Date of download: 10/24/2017 Copyright © 2012 American Medical Association. All rights reserved.
Copyright © 2012 American Medical Association. All rights reserved. From: Tests and Expenditures in the Initial Evaluation of Peripheral Neuropathy Arch Intern Med. 2012;172(2):127-132. doi:10.1001/archinternmed.2011.1032 Figure Legend: Figure 3. Utilization of common diagnostic tests in 1031 patients with peripheral neuropathy. ANA indicates antinuclear antibody; CBC, complete blood cell count; CMP, comprehensive metabolic panel; ESR, erythrocyte sedimentation rate; PT, prothrombin time; and PTT, partial thromboplastin time. Date of download: 10/24/2017 Copyright © 2012 American Medical Association. All rights reserved.